The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes

Michèle Saïdi (1, 2) , Isabelle Brochériou (2, 1) , Emmanuel Estève (3, 1) , Sophie Tuffet (4) , Zahir Amoura (2) , Makoto Miyara (2) , Xavier Belenfant (5) , Tim Ulinski (6) , Philippe Rouvier (2) , Hanna Debiec (1) , Pierre Ronco (1) , David Buob (1, 2)

1 Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation
2 CHU Pitié-Salpêtrière [AP-HP]
3 CHU Tenon [AP-HP]
4 CIC Paris-Est - Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière]
5 CHI André Gregoire - Centre Hospitalier Intercommunal André Grégoire [Montreuil]
6 CHU Trousseau [APHP]

Exostosin (EXT) 1 and EXT2 proteins are recently discovered major components of the subepithelial deposits in a subset of patients with membranous nephropathy (MN).1,2 Although the detection of EXT1/2 seems to be a distinctive feature of MN related to systemic lupus erythematosus (SLE),1 the exact frequency of EXT-positive, SLE-associated MN (SLE-MN) and its potential clinical significance are not well determined. Here, we retrospectively evaluated 86 consecutive patients with biopsy-proven pure class 5 SLE-MN diagnosed between January 2010 and December 2018 in 2 nephropathology centers (La Pitié Salpêtrière and Tenon hospitals) in Paris, France; mixed classes (3 + 5 and 4 + 5 of the 2003 ISN/Renal Pathology Society classification)3 were excluded.

Mots clés: exostosin; immunohistochemistry; membranous nephropathy; renal biopsy; systemic lupus erythematosus; exostosin

Domaines: Urologie et Néphrologie; Immunité adaptative

Michèle Saïdi, Isabelle Brochériou, Emmanuel Estève, Sophie Tuffet, Zahir Amoura, et al.. The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes. Kidney International Reports, 2021, 6 (7), pp.1977 - 1980. ⟨10.1016/j.ekir.2021.04.025⟩. ⟨hal-03335588⟩